Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
- Mechanism
- Curator reviewed
RSIFN-co has immunomodulation, antiviral, and antineoplastic activities. It binds to IFN-specific cell surface receptors and causes transcription and translation of genes that have protein products with antiviral, antiproliferative, anticancer, and immunomodulating effects. It is currently being investigated for viral diseases and cancer.
- Also known as
- rSIFN-co
- Code names
- Recombinant Super-Compound Interferon
What you can answer from here — as of April 23, 2025
Which companies are running trials of Recombinant Super-Compound Interferon, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account